Clinical outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency (PTPSd)
Objective: To assess morbility and clinical outcome of patients affected by defect of tetrahydrobiopterin (BH4) synthesis due to PTPSd. Background: PTPSd is a treatable genetic disorder…Loss‐of‐function mutations in NR4A2 cause dopa‐responsive dystonia-parkinsonism
Objective: To report two patients with early-onset dystonia-parkinsonism as a result of loss-of-function mutations in nuclear receptor subfamily 4 group A member 2 (NR4A2). Background:…Usability assessments in patients with Parkinson’s disease: The foundation for a holistic telemedical solution (TelePark)
Objective: The TelePark project has the objective to develop a holistic telemedicine platform for patients with Parkinson’s disease. For a successful implementation, it is necessary…Automated Capture of Deep Brain Stimulation Settings & Clinical Outcomes
Objective: To automate capture of deep brain stimulation (DBS) settings and clinical outcomes during programming for movement disorders. Background: DBS programming involves testing a wide…Feasibility of a simplified, symptom-based electronic diary to improve evaluation of motor and non-motor complications in Parkinson’s disease
Objective: To determine the feasibility of the simplified and symptom-based electronic PD diary and compare with the standard paper diary. Background: Motor complications (MC) is…Visuomotor reaction time can predict IQ in children
Objective: This study investigated whether visuomotor reaction time in 5 year-old children predicts intelligence test scores in 8 year-old children using the longitudinal approach. Background:…Home Based Care: A care pathway innovation for Parkinson’s disease
Objective: To create a new care pathway that puts the needs of the patient at the centre of service design and delivery. Background: The traditional…Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…A Human Factors Study of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer oral LD/CD into the mouths of patients with PD. The System is…Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?
Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »